Pyrimidine Derivatives for RSV Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory syncytial virus (RSV) infections, particularly for those beyond preterm infants at high risk, lack effective therapeutic options and have limited utility due to pharmacokinetic constraints, necessitating the development of alternative compounds with favorable pharmacokinetic profiles.
Innovation Solution
A novel series of pyrimidine compounds with specific structural features, including various substituents and linkages, are identified as active RSV inhibitors, offering potential therapeutic benefits with improved pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If palivizumab monoclonal antibody is used for RSV prophylaxis, then protection against RSV infection is achieved in preterm infants and high-risk infants, but the treatment is unavailable for other patient populations due to restricted utility and pharmacokinetic constraints
Solution Approach 1:
The patent applies parameter changes by developing small molecule pyrimidine compounds with modified pharmacokinetic parameters (oral bioavailability, half-life, tissue penetration) compared to the monoclonal antibody palivizumab. The compounds of formula (I) and their pharmaceutically acceptable salts are designed to achieve sustained antiviral activity through optimized molecular structure, enabling broader patient population coverage while maintaining protection efficacy.
2Reliability
If existing anti-RSV compounds are developed, then some RSV inhibition activity is achieved, but favorable pharmacokinetic profiles are not obtained limiting therapeutic utility
Solution Approach 1:
The patent systematically optimizes pharmacokinetic parameters by varying substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, Ra, and linkage Z in the pyrimidine compound structure. This structural parameter optimization enables the compounds to achieve both reliable RSV inhibition activity and favorable pharmacokinetic profiles including improved oral bioavailability, extended half-life, and enhanced tissue distribution.
Solution Approach 2:
The patent creates composite molecular structures by combining the pyrimidine core with various aromatic or heteroaromatic rings (such as phenyl, pyridyl, pyrimidinyl groups) and substituent patterns. These composite structures integrate multiple functional moieties that collectively provide both antiviral activity and optimized pharmacokinetic properties that neither component achieves alone.
Data Source
AI summary
Pyrimidine derivatives of formula (I) wherein: Z is a direct bond or -(CH2)n- wherein n is 1 or 2; one of X and Y is N, CH or CF, and the other of X and Y is CH; one of R1 and R2 is selected from -NHR, -NR2, -OR, -SR, -S(O)R, -S(O)2R and a group of the following formula (A) and the other of R1 and R2 is selected from -NHR', -OH, -OR' and a group of the above formula (A); R is unsubstituted C1-C6 alkyl; R' is a group selected from C1-C6 alkyl, 5- to 12-membered aryl and C3-C6 cycloalkyl, which group is unsubstituted or substituted; W is -(CH2)m-, -CH2-O-CH2-, -CH2-S-CH2- or -CH2-S(O)2-CH2-; p is 1, q is an integer of 1 - 6 and V is N; or p is 1, q is 0 and V is CH; or p is 0, q is 0 and V is N; r is 0 or 1; and R3 is -(CH2)s-NH2 or -(CH2)s-OH wherein s is 0 or an integer of 1 to 4; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.